Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovaxin in CIS or RR-MS
NCT00245622Phase 2Completed
- Sponsor
- Opexa Therapeutics
- Start
- May 2006
- Primary completion
- Sep 2008
- Modality
- Native Immune Cells, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) comparing Tovaxin with Placebo (2 arms). Primary endpoints: Cumulative number of gadolinium-enhancing lesions at 1 year and Adverse Events at 1 year. Started May 2006; status: completed.
02
Drugs
tovaxin
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT00245622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245622.